Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Dilated Cardiomyopathy Therapeutic Market is projected to register a CAGR of 3.6% during the forecast period.

The COVID-19 pandemic had a significant impact on dilated cardiomyopathy therapeutics market. For instance, according to an article titled “A case of Dilated Cardiomyopathy in COVID-19,” published in May 2022, comparing cardiac cases in COVID-19 to respiratory cases, cardiac injury was documented in 19.7% to 29.8% of instances. Numerous pathways have contributed to the involvement of the cardiac myocardium in COVID-19, and up to 20–30% of hospitalized patients exhibit this involvement, as seen by high troponin levels. Similarly, in an article titled “Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis,” published in April 2022, between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19 are thought to experience AM. Hence, this is likely to create more demand for dilated cardiomyopathy therapeutics during the pandemic. However, the postponed treatment procedures and surgeries resumed worldwide, driving the market's growth during the post-pandemic period. Therefore, the high number of heart treatment procedures and operations being performed is expected to boost the growth of the dilated cardiomyopathy therapeutics market during the forecast period.

The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are the increasing prevalence of heart diseases and increasing drug and alcohol abuse. For instance, according to an article published by the National Library of Medicine, in May 2022, around 1.5 million cases of myocarditis occur each year in the entire world. The incidence rate is often calculated as 10 to 20 cases per 100,000 people. Also, according to an article published in 2022, alcohol-induced toxicity leads to non-ischemic dilated cardiomyopathy characterized by loss of contractile function and dilatation of myocardial ventricles. Hence, alcohol use is an important cause of non-ischemic cardiomyopathy and accounts for 10% of all cases of dilated cardiomyopathies. Additionally, according to an article published by Wolters Kluwer, in January 2022, alcohol-induced cardiomyopathy is a type of acquired dilated cardiomyopathy caused by long-term heavy alcohol consumption. It also stated that the prevalence of alcohol-induced cardiomyopathy among patients with heart failure (HF) or dilated cardiomyopathy depends on the threshold alcohol consumption used to identify alcohol-induced cardiomyopathy.

Furthermore, as per an article published by ScienceDirect, in June 2022, substantial proportions of youth surveyed had tried illicit drugs at least once in the countries such as Australia (greater than 40%), Canada (greater than35%), Europe (greater than 23% boys, 17% girls), United States (greater than 40%, more than 25% of 8th graders and nearly half of the 12th graders in the United States reported smoking marijuana daily, and 1 in 7 reported having been a daily marijuana smoker at some time for at least a month. Alcohol use disorder is a common disorder in the United States. The 12-month prevalence of alcohol use disorder is estimated to be 4.6% among 12 to 17-year-olds and 8.5% among adults aged 18 years and older in the United States. Rates of the disorder are greater among adult men (12.4%) than among adult women (4.9%). Twelve-month prevalence of alcohol use disorder among adults decreases in middle age, being greatest among 18 to 29-year-olds (16.2%) and lowest among individuals aged 65 years and older (1.5%). Furthermore, the increasing number of people suffering from cardiac muscle infections, along with drug or alcohol abuse, are also the major factors that help in driving the growth of the market.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However side effects of dilated cardiomyopathy therapeutics are expected to hinder the market growth over the forecast period.

Angiotensin II receptor blockers acquire a significant market share, followed by beta-blockers. This is attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. As per an article published by the National Library of Medicine in June 2022, the effects of angiotensin are lessened by angiotensin II receptor blockers (ARBs). High blood pressure is brought on by this protein's tendency to make blood vessels overly tight. ARBs also treat kidney disease and heart failure, as well as reduce the incidence of heart attacks and strokes. These factors are expected to drive and support segmental growth in the market.

Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. For instance, in September 2021, Otsuka Pharmaceutical Co., Ltd. announced that Novartis Pharma K.K. had obtained approval in Japan for ENTRESTO 100 mg and 200 mg Tablets for the new indication of hypertension. This approval is Japan's first ARNI for the indication of hypertension. The other driving factors of the segment are also related to the increasing prevalence of heart diseases. According to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data updated in July 2022, 1 person dies every 34 seconds in the United States from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020, which is 1 in every 5 deaths. Hence, as the prevalence of heart diseases increases, the growth of the market increases too.

Therefore the above-mentioned factors are expected to drive segmental growth in the market.

North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors.

The United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. According to American Heart Association, data updated in July 2022, The most prevalent kind, dilated cardiomyopathy (DCM), primarily affects adults under the age of 50. It affects the bottom and upper chambers of the heart, the ventricles, and the atria. The left ventricle, the heart's primary pumping chamber, is where the disease frequently develops first. The heart muscle starts to widen, stretch, and get thinner. The interior of the chamber therefore grows. The right ventricle is frequently affected before the atria. These factors are expected to promote the growth of the market in the region.

According to National Heart, Lung, and Blood Institute, data updated in March 2022, about 18.2 million American adults have coronary artery disease, making it the most common type of heart disease in the United States. Therefore as the number of cardiovascular diseases increases the market for dilated cardiomyopathy also increases.

Therefore, the above-mentioned factors are expected to drive the market in the region during the forecast period.

The Dilated Cardiomyopathy Therapeutic Market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer inc., t2cure GmbH, MyoKardia, and Kasiak Research Pvt.ltd., among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support